Shire Articles
Fosrenol approved in Germany for hyperphosphatemia
25 September 2006
Study of ADHD drugs highlights functional differences
18 September 2006
SGX stops Ph II/III Troxatyl AML study
4 September 2006
Shire submits Connexyn NDA to US FDA
4 September 2006
Split patent decison for Amgen and Shire
14 August 2006
Stock Commentary - Europe - week to Aug 7, 2006
7 August 2006
Industry bodies oppose annual revision of Japan
7 August 2006
Shire earnings down on TKT acquisition
7 August 2006
Shire files SPD465 for adult ADHD
31 July 2006
Shire's Elaprase cleared by US regulators
26 July 2006
Stock Commentary - Europe - week to July 10, 2006
17 July 2006
New River files NRP409 IND
10 July 2006
FDA extends review period for Shire's Elaprase
22 May 2006
Shire's net income improves 75% in 1st qtr
8 May 2006
Enrollment continues in Voyager's Ph III AD trial
24 April 2006
Noven's Daytrana gets FDA go-ahead for ADHD
17 April 2006
US FDA urged to warn on ADHD drugs
20 February 2006
Shires pays New River $50M as part of NRP104 accord
13 February 2006
Shire submits EU MAA on ulcerative colitis drug
13 February 2006
Shire Human Genetic Therapies adds to management team
6 February 2006
US FDA accepts NRP104 NDA for ADHD
6 February 2006
Pharma/biotech mergers and acquisitions during 2005
6 February 2006
Stock Commentary - Europe - week to Jan 23
30 January 2006
NICE disappoints in ruling on Alzheimer's
30 January 2006
Shire and Impax settle Adderall dispute
30 January 2006
Adderall litigation update
30 January 2006
Innovata agrees Adept licensing deal
9 January 2006
Shire submits UC NDA on Mesavance
9 January 2006
Noven to start making Daytrana
19 December 2005
Shire/New River submit NRP104 NDA to FDA
12 December 2005
FDA: Shire's Daytrana safe and effective
12 December 2005
Shire submits MAA on idursulfase to EMEA
12 December 2005
Shire submits BLA for Elaprase in MPS
5 December 2005
Shire to set up new listed holding company
19 September 2005
Stock Commentary - Europe - week to Aug 15
5 September 2005
Stock Commentary - Europe
15 August 2005
Stock Commentary - Europe
8 August 2005
Australian PBS adds 45 drugs, widens use for 28
8 August 2005
Shire/TKT merger OKed
8 August 2005
Shareholders approve Shire's buy of TKT
1 August 2005
Shire and Noven resubmit MTS for pediatric ADHD
1 August 2005
Nostrum "confident" on Shire litigation
1 August 2005
TKT urges "yes" vote to Shire's bid
18 July 2005
Two major investors challenge Shire
11 July 2005
Stock Commentary - European
27 June 2005
Stock Commentary - Europe
20 June 2005
Shire acquisition of TKT moves on
20 June 2005
Stock Commentary - Europe
13 June 2005
Stock Commentary - Europe
6 June 2005
Shire finds in vitro efficacy for Fosrenol
23 May 2005
Shire provides key R&D candidates update
16 May 2005
TKT's 1st-qtr losses widen 51%
16 May 2005
TKT assesses impact of fire at production unit
28 April 2005
Stock Commentary - Europe
28 April 2005
New CEO for Transkaryotic Therapies
28 April 2005
UPDATE: Mixed reaction to Shire's $1.6B bid for TKT
27 April 2005
Three firms get US appro to sell generic Agrylin
26 April 2005
Eon Labs wins US FDA approval for generic Agrylin
25 April 2005
Shire Pharma to buy TKT in $1.6M deal
25 April 2005
Shire will not sue Teva over Adderall generic
25 April 2005
Shire launches Equetro in USA
22 April 2005
Positive data for Shire/Noven's ADHD drug
18 April 2005
Stock Commentary - Europe
11 April 2005
New River Pharma's net loss increases
11 April 2005
Upbeat forecast from Shire Pharma
11 April 2005
Shire announces 13% growth in revenue
7 March 2005
UK NICE seeks to curb Alzheimer's drugs
7 March 2005
Stock Commentary - Europe
28 February 2005
Rolf Stahel becomes chairman of PowderMed
28 February 2005
Teva files for generic Adderall in USA
28 February 2005
Stock Commentary - Europe
21 February 2005
New River Pharma gives update on clinical trials and pipeline
21 February 2005
Shire's Adderall withdrawn in Canada
14 February 2005
Shire and River sign deal for ADHA drug
7 February 2005
Positive data for ID Biomedical's flu vacc
24 January 2005
Shire outlicenses HIV candidate to Avexa
24 January 2005
Shire update on generic Adderall cases
24 January 2005
Stock Commentary - European
17 January 2005
ID Bio closes $60M loan transaction
17 January 2005
Lilly adds liver warning to Strattera label
10 January 2005
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
